Regulonix Holding, Inc.
Tucson
About Regulonix Holding, Inc.
Regulonix is an early-stage biotechnology company developing non-opioid drugs for chronic pain. By indirectly targeting the sodium channel NaV1.7 – a well-established and genetically validated pain target – and focusing on the signaling pathways that control this channel’s activity, the Regulonix team has isolated compounds demonstrated in animal models to be non-addictive and more effective than morphine. This unique platform helps address a global pain management therapeutics market projected to reach $83B by 2024, affecting more than 100 million Americans and 1.5 billion people globally.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.0M
- Funding stage: Seed
- Last round: Seed (Jul 2018)
- Website: regulonixinc.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/regulonix-holding-inc-8863 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.